RecruitingPhase 1Phase 2NCT06911333

AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors

A Phase I/IIa Trial of AD1208, a Cell Cycle Inhibitor/MASTL Inhibitor, as a Single Agent or a Combination in Subjects With Any Progressive, Locally Advanced(Unresectable) or Metastatic Solid Tumors

Sponsor

Avelos Therapeutics Inc.

Enrollment

36 participants

Start Date

Mar 11, 2025

Study Type

INTERVENTIONAL

Conditions

Solid Tumor Solid Tumor, Adult Solid Tumor Cancer Tumor, Solid Solid Tumor, Unspecified, Adult Solid Tumors Refractory to Standard Therapy Solid Tumor in Advanced Stage

Summary

The goal of this clinical trial is to evaluate the safety and tolerability of AD1208 to determine the maximum tolerated dose(MTD) or maximumly administered dose(MAD) in any progressive, locally advanced (unresectable) or metastatic solid tumors. The main questions it aims to answer are: * Which dosage of AD1208 is safe and tolerable for participants? * What medical problems do participants have when taking AD1208? Participants will: * Take drug AD1208 every day up to 1 cycle at the least. * Visit the site once every 1 weeks for checkups and tests during cycle 1 and every 3 weeks from cycle 2 onwards. * Keep a diary of any adverse events and administrated drug

Eligibility

Min Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called AD1208 for people with solid tumor, solid tumor cancer, and other related conditions. The study is currently recruiting participants at 3 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.